Haemostatic effects of erythropoietin treatment with and without acetylsalicylic acid in individuals with chronic kidney disease: a prospective single-arm repeated-measures study

Clicks: 11
ID: 339463
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #231 of 233 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 233 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
ABSTRACT Background Erythropoiesis-stimulating agents (ESAs) are used to treat anemia in chronic kidney disease (CKD). ESAs have been associated with increased thrombotic risk, but the underlying mechanisms remain unclear. Given its antiplatelet effects and widespread use in cardiovascular prevention, we hypothesized that concomitant acetylsalicylic acid (ASA) attenuates ESA-induced prothrombotic alterations in hemostasis in patients with CKD. Methods We conducted a prospective single-arm, repeated-measures, interventional phase 4 study in 27 individuals with advanced CKD (hemodialysis, peritoneal dialysis, and non-dialysis). The study comprised four consecutive 4-week phases: ESA washout, ESA treatment, ESA plus ASA (75 mg daily), and post-treatment washout. At the end of each phase, we assessed platelet function, whole-blood coagulation, endothelial activation, coagulation activation, and fibrinolysis. Results ESA treatment induced a modest and reversible increase in platelet count, whereas markers of immature platelets (IPF and H-IPF) decreased. Soluble P-selectin increased slightly during ESA treatment, indicating mild platelet and/or endothelial activation. Platelet aggregation, thromboelastometry parameters, prothrombin fragment 1 + 2, fibrin D-dimer, soluble thrombomodulin, and fibrinolysis markers remained largely unchanged throughout ESA treatment and ASA had no effect on ESA-related changes. Conclusions In individuals with advanced CKD, short-term ESA treatment was associated with modest changes in platelet count and soluble P-selectin but did not result in measurable changes in platelet function, coagulation activity or fibrinolysis. ASA did not modify ESA-related effects and did not induce measurable haemostatic changes. These findings do not support a major systemic procoagulant effect of ESA, indicating that alternative mechanisms might contribute to the increased thrombotic risk observed in clinical trials.
Reference Key
openalex_W7225719746 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag398
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.